文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

靶向治疗对肾细胞癌脑转移患者预后因素、治疗模式及生存的影响

Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-04-12

该多机构回顾性数据库纳入2006年1月1日至2015年12月31日诊断新发脑转移的711例肾细胞癌患者,分析预后因素、治疗模式变化及靶向治疗对生存的影响。既往/当前队列中位生存分别为9.6/12个月(P<.01),全脑放疗使用率从50%降至22%,单用立体定向放射外科从46%升至58%。

要点

  • 既往/当前队列中位生存分别为9.6/12个月,P<.01。
  • 全脑放疗使用率从50%降至22%,单用立体定向放射外科从46%升至58%。
  • 仅脑转移后使用细胞因子与生存改善相关,6类受研究药物中其余未报告此关联。

核心结论

  • 更多预后因素可细化该较大当代队列的预后判断,肾细胞癌脑转移患者治疗模式已改变且生存随时间改善,改善原因尚不明确,可能与更积极使用脑转移局部治疗及对颅外进展患者有更广泛全身治疗选择有关。

研究设计与样本

  • 多机构回顾性、经机构审查委员会批准的数据库,纳入2006年1月1日至2015年12月31日诊断新发脑转移的711例肾细胞癌患者。
  • 将临床参数和治疗与中位生存及从原发诊断至脑转移的时间进行关联,并开展多变量分析。

主要发现

  • 既往/当前队列中位生存分别为9.6/12个月,P<.01。
  • Karnofsky体能状态、颅外转移、脑转移数目和血红蛋白b这4项预后因素对脑转移诊断后生存有显著意义。
  • 研究的6类药物中,仅脑转移后使用细胞因子与生存改善相关。
  • 全脑放疗使用率从50%降至22%,单用立体定向放射外科从46%升至58%。
  • 非神经系统死因是神经系统死因的两倍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify prognostic factors, define evolving patterns of care, and the effect of targeted therapies in a larger contemporary cohort of renal cell carcinoma (RCC) patients with new brain metastases (BM). METHODS AND MATERIALS: A multi-institutional retrospective institutional review board-approved database of 711 RCC patients with new BM diagnosed from January 1, 2006, to December 31, 2015, was created. Clinical parameters and treatment were correlated with median survival and time from primary diagnosis to BM. Multivariable analyses were performed. RESULTS: The median survival for the prior/present cohorts was 9.6/12 months, respectively (P < .01). Four prognostic factors (Karnofsky performance status, extracranial metastases, number of BM, and hemoglobin b) were significant for survival after the diagnosis of BM. Of the 6 drug types studied, only cytokine use after BM was associated with improved survival. The use of whole-brain radiation therapy declined from 50% to 22%, and the use of stereotactic radiosurgery alone increased from 46% to 58%. Nonneurologic causes of death were twice as common as neurologic causes. CONCLUSIONS: Additional prognostic factors refine prognostication in this larger contemporary cohort. Patterns of care have changed, and survival of RCC patients with BM has improved over time. The reasons for this improvement in survival remain unknown but may relate to more aggressive use of local brain metastasis therapy and a wider array of systemic treatment options for those patients with progressive extracranial tumor.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sperduto PW, Deegan BJ, Li J, et al. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. Int J Radiat Oncol Biol Phys. 2018. PMID: 29976497. doi:10.1016/j.ijrobp.2018.04.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。